Cartesian Therapeutics(RNAC)

Focus: Cartesian Therapeutics is a public biotech company specializing in mRNA-engineered cell therapy, with a diversified pipeline targeting autoimmune and oncology indications. The company operates at small scale (1-50 employees) from Frederick, MD with a public listing (RNAC) and $213M cash position.

Gene Therapy Cell Therapy

Profile data last refreshed 16h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

1-50

Open Jobs

3-2 this month

Stable — net -2 jobs in 30d

0 added, 2 removed. Backfill posture.

Should You Work at Cartesian Therapeutics?

AI assessment

High-risk, high-reward opportunity suitable for early-career scientists or strategic hires willing to bet on a novel platform; unsuitable for those seeking stability or established career infrastructure.

Why Work Here

Cutting-edge mRNA-engineered cell therapy platform with multiple clinical programs across high-value indications (lupus, multiple myeloma, myasthenia gravis, ARDS).

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$39M

Pipeline & Clinical Trials

Descartes-25

Multiple Myeloma

PHASE_1

Clinical Trials (1)

NCT05113342Descartes-25 in Relapsed/Refractory Multiple Myeloma

Phase 1

Help build intelligence for Cartesian Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Newly public with strong cash position ($213M FY2025) enabling sustained R&D investment and reduced near-term layoff risk.

Active hiring in Strategy and Management Consulting signals leadership build-out and potential for rapid career advancement in a small, growing organization.

Watch Out For

Steep cash burn: $77.4M net loss in FY2025 on only $39M revenue (116% R&D intensity) means runway is limited to ~2-3 years without inflection or additional capital.
Tiny headcount (1-50 employees) with only 5 active job openings limits role variety and organizational stability; insider selling reported in recent news signals insider concern about equity value.

Generated by Claude from Cartesian Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Descartes 30

Acute Respiratory Distress Syndrome

PHASE_1

Clinical Trials (1)

NCT04524962Study of Descartes-30 in Acute Respiratory Distress Syndrome

Phase 1

Descartes-11

Multiple Myeloma

PHASE_1

Clinical Trials (1)

NCT03994705Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

Descartes-15

Refractory Multiple Myeloma

PHASE_1

Clinical Trials (1)

NCT06304636Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

Descartes-08

Multiple Myeloma

PHASE_1

Clinical Trials (1)

NCT03448978Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Phase 1

Descartes-08

Childhood-onset Systemic Lupus Erythematous

PHASE_1_2

Clinical Trials (1)

NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Phase 1/2

Descartes 11

Multiple Myeloma

PHASE_2

Clinical Trials (1)

NCT04436029Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Phase 2

Descartes-08

Systemic Lupus Erythematosus (SLE)

PHASE_2

Clinical Trials (1)

NCT06038474Descartes-08 for Patients With Systemic Lupus Erythematosus

Phase 2

Descartes-08

Myasthenia Gravis, Generalized

PHASE_2

Clinical Trials (1)

NCT04146051Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Phase 2

Descartes 08

Myeloma Multiple

PHASE_2

Clinical Trials (1)

NCT04816526Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Phase 2

Descartes-08

Antisynthetase Syndrome

PHASE_2

Clinical Trials (1)

NCT07391605Descartes-08 in Autoantibody Myositis

Phase 2

Decartes-08

Myasthaenia Gravis

PHASE_3

Clinical Trials (1)

NCT06799247Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis